Study to understand clinical characteristics, treatment pathway in chronic lymphocytic leukemia

Trial Identifier: D8220R00031
Sponsor: AstraZeneca
NCTID:: NCT04964908
Start Date: December 2021
Primary Completion Date: March 2023
Study Completion Date: March 2023
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Argentina Argentina, Argentina
Colombia Colombia, Colombia
Dominican Republic Dominican Republic, Dominican Republic
Egypt Cairo, Egypt
India Ahmedabad, India
India Bangalore, India
India Faridabad, India
India Hitech, India
India New Delhi, India
India Shibpur, India
Kuwait Kuwait, Kuwait
Saudi Arabia Jeddah, Saudi Arabia
Saudi Arabia Riyadh, Saudi Arabia
Turkey Adana, Turkey
Turkey Ankara, Turkey
Turkey Izmir, Turkey
Turkey Samsun, Turkey